Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Prostate Cancer

  Free Subscription


08.05.2017

9 BJU Int
1 Br J Cancer
1 Cancer
1 Cancer Lett
2 Eur Urol
2 Int J Cancer
5 Int J Radiat Oncol Biol Phys
2 Int J Urol
1 J Cell Physiol
1 J Clin Oncol
7 J Nucl Med
1 Nat Rev Urol
1 PLoS One
1 Prog Urol
1 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BJU Int

  1. ANDERSON CB, Tin AL, Sjoberg DD, Mulhall JP, et al
    Association between number of prostate biopsies and patient-reported functional outcomes after radical prostatectomy: implications for active surveillance protocols.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available

  2. DE NUNZIO C, Presicce F, Lombardo R, Cancrini F, et al
    Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available

  3. ZUMSTEG ZS, Zelefsky MJ, Woo KM, Spratt DE, et al
    Unification of favorable intermediate, unfavorable intermediate, and very high risk-stratification criteria for prostate cancer.
    BJU Int. 2017 May 2. doi: 10.1111/bju.13903.
    PubMed     Text format     Abstract available

  4. MATARAZA JM, Gotwals P
    Recent advances in immuno-oncology and its application to urological cancers.
    BJU Int. 2016;118:506-14.
    PubMed     Text format     Abstract available

  5. DEVECI S, Gotto GT, Alex B, O'Brien K, et al
    A survey of patient expectations regarding sexual function following radical prostatectomy.
    BJU Int. 2016;118:641-5.
    PubMed     Text format     Abstract available

  6. WATSON E, Shinkins B, Frith E, Neal D, et al
    Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available

  7. WYSOCK JS, Mendhiratta N, Zattoni F, Meng X, et al
    Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results.
    BJU Int. 2016;118:515-20.
    PubMed     Text format     Abstract available

  8. MURRAY NP, Aedo S, Reyes E, Orellana N, et al
    Prediction model for early biochemical recurrence after radical prostatectomy based on the Cancer of the Prostate Risk Assessment score and the presence of secondary circulating prostate cells.
    BJU Int. 2016;118:556-62.
    PubMed     Text format     Abstract available

  9. DINH KT, Mahal BA, Ziehr DR, Muralidhar V, et al
    Risk of prostate cancer mortality in men with a history of prior cancer.
    BJU Int. 2016;117.
    PubMed     Text format     Abstract available


    Br J Cancer

  10. BARRY KH, Moore LE, Sampson JN, Koutros S, et al
    Prospective study of DNA methylation at chromosome 8q24 in peripheral blood and prostate cancer risk.
    Br J Cancer. 2017 May 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Cancer

  11. VETTERLEIN MW, Loppenberg B, Karabon P, Dalela D, et al
    Impact of travel distance to the treatment facility on overall mortality in US patients with prostate cancer.
    Cancer. 2017 May 4. doi: 10.1002/cncr.30744.
    PubMed     Text format     Abstract available


    Cancer Lett

  12. BRIZZOLARA A, Benelli R, Vene R, Barboro P, et al
    The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
    Cancer Lett. 2017 Apr 25. pii: S0304-3835(17)30285.
    PubMed     Text format     Abstract available


    Eur Urol

  13. YANG JC, Evans CP
    Adjunct Screening of NKX3.1 Expression Supports 5alpha-Reductase Inhibition Intervention in Prostate Cancer Active Surveillance.
    Eur Urol. 2017 Apr 25. pii: S0302-2838(17)30327.
    PubMed     Text format    

  14. PATEL DN, Freedland SJ
    New Prostate Cancer Biomarkers: The Search Continues.
    Eur Urol. 2017 Apr 24. pii: S0302-2838(17)30293.
    PubMed     Text format    


    Int J Cancer

  15. LUBIK AA, Nouri M, Truong S, Ghaffari M, et al
    Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.
    Int J Cancer. 2017;140:358-369.
    PubMed     Text format     Abstract available

  16. TRABERT B, Eldridge RC, Pfeiffer RM, Shiels MS, et al
    Pre-diagnostic circulating inflammation markers and endometrial cancer risk in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
    Int J Cancer. 2016 Oct 22. doi: 10.1002/ijc.30478.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  17. YANG DD, Muralidhar V, Mahal BA, Labe SA, et al
    National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer.
    Int J Radiat Oncol Biol Phys. 2017;98:338-343.
    PubMed     Text format     Abstract available

  18. SHENG Y, Li T, Lee WR, Yin FF, et al
    Exploring the Margin Recipe for Online Adaptive Radiation Therapy for Intermediate-Risk Prostate Cancer: An Intrafractional Seminal Vesicles Motion Analysis.
    Int J Radiat Oncol Biol Phys. 2017;98:473-480.
    PubMed     Text format     Abstract available

  19. LAWTON CAF, Lin X, Hanks GE, Lepor H, et al
    Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
    Int J Radiat Oncol Biol Phys. 2017;98:296-303.
    PubMed     Text format     Abstract available

  20. O'CALLAGHAN ME, Raymond E, Campbell JM, Vincent AD, et al
    Patient-Reported Outcomes After Radiation Therapy in Men With Prostate Cancer: A Systematic Review of Prognostic Tool Accuracy and Validity.
    Int J Radiat Oncol Biol Phys. 2017;98:318-337.
    PubMed     Text format     Abstract available

  21. SPRATT DE, Jagsi R
    Breast and Prostate Cancer: Lessons to Be Shared.
    Int J Radiat Oncol Biol Phys. 2017;98:263-268.
    PubMed     Text format    


    Int J Urol

  22. OKIHARA K, Yorozu A, Saito S, Tanaka N, et al
    Assessment of sexual function in Japanese men with prostate cancer undergoing permanent brachytherapy without androgen deprivation therapy: Analysis from the Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation database.
    Int J Urol. 2017 Apr 28. doi: 10.1111/iju.13358.
    PubMed     Text format     Abstract available

  23. TERADA N, Maughan BL, Akamatsu S, Kobayashi T, et al
    Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naive castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
    Int J Urol. 2017 Apr 28. doi: 10.1111/iju.13346.
    PubMed     Text format     Abstract available


    J Cell Physiol

  24. BORGES GT, Vencio EF, Quek SI, Chen A, et al
    Conversion of Prostate Adenocarcinoma to Small Cell Carcinoma-Like by Reprogramming.
    J Cell Physiol. 2016;231:2040-7.
    PubMed     Text format     Abstract available


    J Clin Oncol

  25. PARIKH RR, Kim IY
    Can Genomic Data Guide the Postoperative Management of Prostate Cancer?
    J Clin Oncol. 2017 May 4:JCO2017724849. doi: 10.1200/JCO.2017.72.4849.
    PubMed     Text format    


    J Nucl Med

  26. PIERT M, Montgomery J, Kunju LP, Siddiqui J, et al
    18F-choline PET/MRI: the Additional Value of PET for MRI-guided Transrectal Prostate Biopsies.
    J Nucl Med. 2016 Mar 16. pii: jnumed.115.170878.
    PubMed     Text format     Abstract available

  27. ZHANG J, Niu G, Lang L, Li F, et al
    Clinical translation of a dual integrin alphavbeta3 and GRPR targeting PET radiotracer 68Ga-NOTA-BBN-RGD.
    J Nucl Med. 2016 Aug 4. pii: jnumed.116.177048.
    PubMed     Text format     Abstract available

  28. D'SOUZA JW, Hensley H, Doss M, Beigarten C, et al
    Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-based Positron Emission Tomography Radiotracers.
    J Nucl Med. 2016 Aug 18. pii: jnumed.116.178780.
    PubMed     Text format     Abstract available

  29. JANI A, Schreibmann E, Rossi PJ, Shelton JW, et al
    Impact of Fluciclovine (18F) Positron Emission Tomography on Target Volume Definition for Post-Prostatectomy Salvage Radiotherapy: Initial Findings from a Randomized Trial.
    J Nucl Med. 2016 Sep 8. pii: jnumed.116.176057.
    PubMed     Text format     Abstract available

  30. HOPE TA, Truillet CC, Ehman EC, Afshar-Oromieh A, et al
    Imaging Response to Androgen Receptor Inhibition Using 68Ga-PSMA-11 PET: First Human Experience.
    J Nucl Med. 2016 Sep 22. pii: jnumed.116.181800.
    PubMed     Text format     Abstract available

  31. WONDERGEM M, van der Zant F, Knol R, Lazarenko S, et al
    18F-DCFPyL PET/CT in the detection of prostate cancer at 60 and 120 minutes ; detection rate, image quality, activity kinetics and biodistribution.
    J Nucl Med. 2017 Apr 27. pii: jnumed.117.192658. doi: 10.2967/jnumed.117.192658.
    PubMed     Text format     Abstract available

  32. KELLY JM, Amor-Coarasa A, Nikolopoulou A, Wustemann T, et al
    Double Targeting Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer.
    J Nucl Med. 2017 Apr 27. pii: jnumed.116.188722. doi: 10.2967/jnumed.116.188722.
    PubMed     Text format     Abstract available


    Nat Rev Urol

  33. STONE L
    Prostate cancer: Transdifferentiation results in resistance.
    Nat Rev Urol. 2017 May 3. doi: 10.1038/nrurol.2017.
    PubMed     Text format    


    PLoS One

  34. AL AAMERI RFH, Sheth S, Alanisi EMA, Borse V, et al
    Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol.
    PLoS One. 2017;12:e0177198.
    PubMed     Text format     Abstract available


    Prog Urol

  35. COHEN J, Andre C, Mozer P
    [Targeted MRI prostate biopsies].
    Prog Urol. 2016;26:854-859.
    PubMed     Text format     Abstract available


    Urology

  36. DAVIS K, Bellini P, Hagerman C, Zinar R, et al
    Physicians' Perceptions of Factors Influencing the Treatment Decision-Making Process for Men with Low-Risk Prostate Cancer.
    Urology. 2017 Apr 25. pii: S0090-4295(17)30391.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: